Mallinckrodt to sell UroCor prostate therapy:
This article was originally published in Clinica
Executive Summary
Mallinckrodt will market and distribute UroCor's prostate cancer radiation therapy through its 35 nuclear medicine pharmacies, independent outlets and its group purchasing contracts. Oklahoma City, Oklahoma-based UroCor's ProstaSeed I-125 pellet device has gained US FDA 510(k) clearance and is awaiting clearance from the Nuclear Regulatory Commission for a launch later this year.